Valuation of medicinal plants for pharmaceutical uses

Current Science

Volumn 86, Issue 7, 2004, Pages 930-937

  Kumar, Pushpam ^a  

^a INSTITUTE OF ECONOMIC GROWTH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4444273152     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Kate, K. and Laird, S. A., The commercial use of biodiversity, Earthscan, London, 1999.
2. Ruitenbeek, H. J., Social cost benefit analysis of the Korup Project, Cameroon, WWF, Godalming, 1989.
3. McAllister, D. E., Estimating the pharmaceutical values of forests, Canadian and Tropical. Can. Biodiversity, 1991, 1.
4. Harvard Business School, INBio/Merck Agreement: Pioneers in sustainable development, NI-593-015, Harvard Business School, Boston, 1992.
5. Godoy, R., Ruben, L. and Anil, M., A method for the valuation of non-timber tropical forest products. Econ. Bot., 1993, 47, 220-233.
6. Cartier, C. M. and Ruitenbeek, H. J., Review of the biodiversity valuation literature. In Issues in Applied Coral Reef Biodiversity Valuation: Results for Montego, Jamaica (ed. Ruitenbeek, H. J.), World Bank Research Committee Project #682-22, The Word Bank, 1999.
7. Farnsworth, N. R. and Soejarto, D. D., Potential consequences of plant extinction in the United States on the current and future avaibility of prospecting drugs. Econ. Bot., 1985, 39, 231-240.
8. Principe, P., Valuing the biodiversity of medicinal plants. In The Conservation of Medicinal Plants (eds Akerele, O. et al.), Cambridge University Press, Cambridge, 1991.
9. Principe, P., Monetising the Pharmacological Benefits of Plants (eds Ballick, M. J. et al.), Medicinal Resources of Tropical Forests, Columbia University Press, 1996.
10. Mendelsohn, R. and Ballick, M. J., The value of undiscovered pharmaceutical in tropical forests. Econ. Bot., 1995, 49.
11. Mendelsohn, R. and Ballick, M. J., Notes on economic plants. Econ. Bot., 1997, 51.
12. DiMasi, J. A., Hansen, R. W., Grabrowski, H. G. and Lasagna, L., Costs of innovation in the pharmaceutical industry. J. Health Econ., 1991, 10, 107-142.
13. Office of Technology Assessment, Pharmaceutical R&D: costs, risks and reward, Technology Report, Govt. Printing Office, Washington, 1993.
14. Aylward, B. A., The economic value of pharmaceutical prospecting and its role in biodiversity conservation, LECC Paper DP 93-03, 1993.
15. Artuso, A., An economic and policy analysis of biochemical prospecting, Pharmaceuticals), Ph.D. dissertation, Cornell University, USA, 1994.
16. Artuso, A., Drugs of Natural Origin: Economic and Policy Aspects of Discovery, Development and Marketing, Haworth Press, New York, 1997.
17. Pearce, D. W. and Puroshothaman, S., The economic value of plants based pharmaceuticals. In Intellectual Property Rights and Biodiversity Conservation (ed. Swanson, T.), Cambridge University Press, Cambridge, 1992.
18. Simpson, R. D., Sedjo, R. A. and Reid, J. W., Valuing biodiversity for use in pharmaceutical research. J. Pol. Econ., 1996, 104.
19. Simpson, R. D., The price of biodiversity. Issues in Science and Technology, Springer, Texas, USA, 1999.
20. Rausser, C. G. and Small, A. A., Valuing research leads: Bioprospecting and the conservation of genetic resources. J. Pol. Econ., 2000, 108.
21. Polasky, S. and Solow, A., On the value of a collection of species. J. Environ. Econ. Manage., 1995, 29.
22. Joglekar, P. and Paterson, M. L., A closer look at the returns and risk of pharmaceutical R&D. J. Health Econ., 1986.
23. Grabowski, H. G. and Vernon, J. M., A new look at the returns and risks to pharmaceutical R&D. Manage. Sci., 1990, 36.
24. Myers, N., Biodiversity's genetic library. In Nature's Services (ed. Daily, G. C.), Island Press, Washington DC, 1997.
25. Myers, N., Threatened biotas: Hotspots in tropical forests. Environmentalist, 1998, 8, 187-208.
26. Artuso, A., The pharmaceutical value of bio-diversity reconsidered. J. Res. Pharmaceut. Econ., 1999, 9, 63-76.